Mutant NRAS was also shown to activate the PI3K/mechanistic target of rapamycin (mTOR)-signaling cascade and combined inhibition of MEK and PI3K was synergistic in certain NRAS mutant cell lines of melanoma, lung cancer and neuroblastoma [14, 15]. The gene discussed is MTOR; the disease is neuroblastoma.